Pain Management in Patients with Advanced Prostate Cancer

ONCOLOGY

Volumn 13, Issue 11, 1999, Pages 1537-1549

  Olson, Karin B ^b   Pienta, Kenneth J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

HUMAN; INTRACTABLE PAIN; MALE; PALLIATIVE THERAPY; PROSTATE TUMOR; REVIEW;

ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; MALE; PAIN, INTRACTABLE; PALLIATIVE CARE; PROSTATIC NEOPLASMS;

EID: 0033220402     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1999.
2. Ferrell BR, Rhiner M, Cohen MZ, et al: Pain as a metaphor of illness. Part I: Impact of cancer pain on family caregivers. Oncol Nurs Forum 18:1303-1309, 1991.
3. Batson OV: The role of vertebral veins in the metastatic process. Ann Intern Med 16:38, 1942.
4. Goltzman D: Mechanisms of the development of osteoblastic metastases. Cancer 80(suppl):1581-1587, 1997.
5. Payne R: Pain management in the patient with prostate cancer. Cancer 71(suppl):1131-1137, 1993.
6. Nielsen O, Munro A, Tannock I: Bone metastases: Pathophysiology and management policy. J Clin Oncol 9:509-524, 1991.
7. Gilbert RW, Kim JH, Posner JB: Epidural spinal cord compression from metastatic tumor: Diagnosis and treatment. Ann Neurol 3:40-51, 1978.
8. Janjan NA: Radiation for bone metastases. Cancer 80(suppl):1628-1645, 1997.
9. Grant R, Papadopoulos SM, Greenberg HS: Metastatic epidural spinal cord compression. Neurol Clin 9:825-841, 1991.
10. Jacox A, Carr DB, Payne R, et al: Management of Cancer Pain: Clinical Practice Guideline No 9. AHCPR publication no. 94-0592. Rockville, Maryland, Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service, March 1994.
11. World Health Organization: Cancer Pain Relief and Palliative Care. Report of a WHO Expert Committee. World Health Organization Technical Report Series, 804, pp 1-75. Geneva, Switzerland, World Health Organization, 1990.
12. Eisenberg E, Berkey CS, Carr DR, et al: Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: A meta-analysis. J Clin Oncol 12:2756-2765, 1994.
13. Hollander D: Gastrointestinal complications of nonsteroidal antiinflammatory drugs: Prophylactic and therapeutic strategies. Am J Med 96:274-281, 1994.
14. Valentini M, Gannizzaro R, Poletti M, et al: Nonsteroidal antiinflammatory drugs for cancer pain: Comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol 13:2637-2642, 1995.
15. Sunshine A, Olson NZ: Non-narcotic analgesics, in Wall PD, Melzack R (eds): Textbook of Pain, 2nd ed, pp 670-685. New York, Churchill Livingstone, 1989.
16. Norrish AE, Jackson RT, McRae C: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 77:511-515, 1998.
17. Chaudry AA, Wahle KW, McClinton S, et al: Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: Effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 57:176-180, 1994.
18. Vijoen TC, VanAswegen CH, DuPlessius DJ: Influence of acetylsalicylic acid and metabolites on DU-145 prostatic cancer cell proliferation. Oncology 52:465-469, 1995.
19. Rose DP, Connolly JM: Effects of fatty acids and eicosanoid synthesis on the growth of two prostate cancer cell lines. Prostate 18:243-254, 1991.
20. Lipman A: Clinically relevant differences among the opioid analgesics. Am J Hosp Pharm 47(suppl):S7-S13, 1990.
21. Levy MH: Pharmacologic management of cancer pain. Semin Oncol 21:718-739, 1994.
22. Thirlwell MP, Sloan PA, Maroun JA, et al: Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 63(suppl):2275-2283, 1989.
23. Glare PA, Walsh TD: Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol 11: 973-978, 1993.
24. Payne R: Transdermal fentanyl: Suggested recommendations for clinical use. J Pain Symptom Manage 7(suppl):540-544, 1992.
25. Payne R, Mathias SD, Pasta DJ, et al: Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl vs oral morphine. J Clin Oncol 16:1588-1593, 1998.
26. DeConno F, Groff L, Brunelli C, et al: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 14:2836-2842, 1996.
27. Fainsinger R, Schoeller T, Bruera E: Methadone in the management of cancer pain: A review. Pain 52:137-147, 1993.
28. Bruera E, Brenneis C, Paterson AH: Use of methlyphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 4:3-6, 1989.
29. American Pain Society: Principles of Analgesic Use in the Treatment of Acute Pain and Chronic Cancer Pain: A Concise Guide to Medical Practice. Skokie, Illinois, American Pain Society, 1992.
30. Rogers M, Watts DJ, Russell RGG: Overview of bisphosphonates. Cancer 80(suppl):1652-1660, 1997.
31. Koizumi M, Yamada Y, Takiguchi T, et al: Bone metabolic markers in bone metastasis. J Cancer Res Clin Oncol 121:542-548, 1995.
32. Urwin GH, Percival RC, Harris S, et al: Generalized increase in bone resorption in carcinoma of the prostate. Eur J Urol 57:721-723, 1985.
33. Clark NW, McClure J, George NJR: Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 68:74-80, 1991.
34. Bishop M, Fellow G: Urinary hydroxyproline excretion - a marker of bone metastases in prostatic carcinoma. Br J Urol 49:711-718, 1977.
35. Boissier S, Magnetic S, Frappart L, et al: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890-3894, 1997.
36. Adami S: Bisphosphonates in prostate carcinoma. Cancer 80(suppl):1674-1679, 1997.
37. Bloomfield DJ: Should bisphosphonates be part of the standard therapy for patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16:1218-1225, 1998.
38. Coleman, RE, Purohit OP, Vinholes JJ, et al: High dose pamidronate: Clinical and biochemical effects in metastatic bone disease. Cancer 80(suppl):1652-1660, 1997.
39. Lipton A, Glover D, Harvey H, et al: Pamidronate in the treatment of bone metastases: Result of two dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 5(suppl):31-35, 1994.
40. Clarke NW, McClure J, George NJR: Clinical and metabolic effects of disodium pamidronate in metastatic prostate cancer, in Bijvoet OLM. Lipton A (eds): Osteoclastic Inhibition in the Management of Malignancy-Related Bone Disorders, pp 54-63. Toronto, Hogrefe and Huber, 1991.
41. Tyrrell CJ, Collinson M, Madsen EL, et al: Intravenous pamidronate: Infusion rate and safety. Ann Oncol 5(suppl):27-29, 1994.
42. Vilimovskij, A, Thuerlimann B, Berenson JR, et al: Renal safety and tolerability of Aredia (pamidronate) administered as an intravenous 1-hour infusion: Preliminary results (abstract). Proc Am Soc Clin Oncol 18:576a, 1999.
43. Pelger RC, Hamdy NA, Zwinderman AH, et al: Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone 22:403-408, 1998.
44. Robinson RG, Blake GE, Preston DF, et al: Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 64:816-822, 1989.
45. Breen SL, Powe JE, Porter AT: Dose estimation in strontium-89 radiotherapy of metastatic prostate cancer. J Nucl Med 33:1316-1323, 1992.
46. Robinson RG, Preston D, Schiefelbein BHS, et al: Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA 274:420-424, 1995.
47. Catton C, Gospodarowicz M: Palliative radiotherapy in prostate cancer. Semin Urol Oncol 15:65-72, 1997.
48. Porter AT, McEwan AJB, Powe JE, et al: Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993.
49. Quilty P, Kirk D, Bolger J, et al: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33-40, 1994.
50. Dearnaley D, Bayly RJ, A'hern RP, et al: Palliation of bone metastases in prostate cancer. Hemibody radiation or strontium-89? Clin Oncol 4:101-107, 1992.
51. Ahonen A, Joensuu H, Hiltunen J, et al: Samarium-153 EDTMP in bone metastases. J Nucl Biol Med 28(supp):123-127, 1994.